Komori
Changes in Officers331AMedix Inc.Information and Communications, Services and Others

Notice Regarding an Additional Change in Representative Director and Executive Appointments

The representative director and president will change from Tanaka Masanori (田中 正則) to Baba Akihiko (馬場 昭彦), while Tanaka Masanori (田中 正則) will change from representative director and president to representative director and chairman. Koyanaka Kazuki (小谷中 一樹) has been nominated as a candidate for director, and 4 directors who serve as Audit and Supervisory Committee members have been nominated for reappointment.

Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Who is moving to which position

Resolved 26 May 2026

Incoming appointee

2 items
Scheduled Appointment Date26 June 2026 (subject to formal approval at the 43rd Annual General Meeting of Shareholders scheduled for 26 June 2026 and at the subsequent meeting of the Board of Directors)
Baba Akihiko (馬場 昭彦)
Previous positionDirector in charge of administration
New positionRepresentative Director and President
生年月日 18 March 1971入社年 2023所有株式数 75,000 shares (record date: Not disclosed)
Koyanaka Kazuki (小谷中 一樹)
Previous positionNew Business Development, Strategy Promotion Unit
New positionCandidate for Director (excluding directors who serve as Audit and Supervisory Committee members)
生年月日 18 June 1971入社年 1998所有株式数 510,000 shares (record date: Not disclosed)

Departing officer

2 items
Tanaka Masanori (田中 正則)Next role stated
Former PositionRepresentative Director and President
New positionRepresentative director and chairman
Baba Akihiko (馬場 昭彦)Next role stated
Former PositionDirector in charge of administration
New positionRepresentative Director and President

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Tanaka Masanori (田中 正則) and Baba Akihiko (馬場 昭彦) will both remain on the Board of Directors (according to the disclosure, they are scheduled to become representative director and chairman and representative director and president, respectively).

Shareholders’ meeting approvalRequired. The proposals for the election of directors are scheduled to be submitted to the 43rd Annual General Meeting of Shareholders, scheduled for 26 June 2026, followed by formal approval by the Board of Directors.
Reason for change

To further strengthen the Company's management structure going forward

Who is moving to which position
ItemDetails
Resolution date26 May 2026
Scheduled Appointment Date26 June 2026 (subject to formal approval at the 43rd Annual General Meeting of Shareholders scheduled for 26 June 2026 and at the subsequent meeting of the Board of Directors)
Name of appointeeBaba Akihiko (馬場 昭彦), Koyanaka Kazuki (小谷中 一樹)
Appointee's new positionRepresentative Director and President, Candidate for Director (excluding directors who serve as Audit and Supervisory Committee members)
Appointee's previous positionDirector in charge of administration, New Business Development, Strategy Promotion Unit
Appointee's date of birth18 March 1971, 18 June 1971
Year the appointee joined the Company2023, 1998
Number of shares held by the appointee75,000 shares (record date: Not disclosed), 510,000 shares (record date: Not disclosed)
Name of departing officerTanaka Masanori (田中 正則), Baba Akihiko (馬場 昭彦)
Former position of departing officerRepresentative Director and President, Director in charge of administration
New position of departing officerRepresentative director and chairman, Representative Director and President
Whether the incumbent will remain in officeTanaka Masanori (田中 正則) and Baba Akihiko (馬場 昭彦) will both remain on the Board of Directors (according to the disclosure, they are scheduled to become representative director and chairman and representative director and president, respectively).
Reason for changeTo further strengthen the Company's management structure going forward
Subject to Approval by the General Meeting of ShareholdersRequired. The proposals for the election of directors are scheduled to be submitted to the 43rd Annual General Meeting of Shareholders, scheduled for 26 June 2026, followed by formal approval by the Board of Directors.
Items this document does not state (7)
Date of departureReason for departureReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To further strengthen the Company's management structure going forward

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding an Additional Change in Representative Director and Executive Appointments | Medix Inc. (331A) timely disclosure | Komori